International Oncolytic Virus Conference
9 - 12 April, Oxford
The excitement and speed of development of this field is now quite astonishing, and surpasses anything that could have been envisaged when conference programme began, back in the early 2000's. Spurred on by the licensure of Imlygic and dramatic advances in cancer immunotherapy, the field of oncolytic viruses provides an enviable platform for targeting therapy, including immunotherapy, selectively to tumours. Innovative molecular science can now be exploited directly in the context of improved cancer treatments, and a raft of new licensed products are expected in the next few years. Rarely have scientists been able to practice their craft in such a high-profile and dynamic environment.